Biomarker ID 2582 |
| Detailed information | |
|---|---|
| CancerLivER ID | 2582 |
| Biomarker | Mannose receptor C type 1, BCL2/adenovirus E1B 19 kD interacting protein 3 like, v-fos FBJ murine osteosarcoma viral oncogene homolog, Ficolin 3 (Hakata antigen), Calmodulin 1, v-maf musculoaponeurotic fibrosarcoma oncogene homolog, Metallothionein 1H, Metallothionein 1E, Solute carrier family 31 me |
| Biomarker Name/Symbol (given in Publication) | Mannose receptor C type 1, BCL2/adenovirus E1B 19 kD interacting protein 3-like, v-fos FBJ murine osteosarcoma viral oncogene homolog, Ficolin 3 (Hakata antigen), Calmodulin 1, v-maf musculoaponeurotic fibrosarcoma oncogene homolog, Metallothionein 1H, Metallothionein 1E, Solute carrier family 31 member1, RAB14 member RAS oncogene family, RNA helicase-related protein, Metallothionein 1F, Metallothionein 1B, Deoxyribonuclease I-like 3, Orosomucoid 1, Metallothionein 3, Mitogen inducible 2, Unknown, Insulin-like growth factor binding protein 4, Insulin-like growth factor binding protein 3, Amylo-1, 6-glucosidase 4-alpha-glucanotransferase, PHD zinc finger protein XAP135 isoform b, Prolylcarboxypeptidase (angiotensinase C), Inhibitor of DNA binding 2, Autocrine motility factor receptor, KIAA0940 protein, Insulin-like growth factor binding protein 4, Complement component 1 r subcomponent |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential prognostic marker for grade progression of HCC and associated invasion and with metastsis of HCC; but not validated on indepedent dataset |
| Experimental Condition | non-tumorous livers L1 (with HCV infection) v/s G1 (well differentiated) HCV-HCC; associated with invasion or metastsis |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in G1 than L1 (with fisher ratio more than 9) |
| Level of significance | P = 0.001 |
| Source | Tissue |
| PMID | 15710396 |
| Type of Biomarker | Prognostic |
| Pathway | induces apoptosis of some types of cancer cells, and IGFBP4 acts as an inhibitor of IGF-in- duced cell proliferation. |
| Cohort | 76 HCC samples : 50 were sero- positive for HCV antibody (HCVAb) and seronegative for hepatitis B virus surface antigen (HBsAg) and among 50 (7G1 (well differentiated, 35 G2 (moderately differentiated) and 10 G3 (poorly differentiated); 26 were seronegative for HCVAb |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Hepatocellular carcinoma (HCC) samples with positive hepatitis C virus (HCV) serology (well (G1), moderately (G2), and poorly (G3) differentiated tumors) with and without HCV infection. |
| Year of Publication | 2005 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |